Evidence map›Paper›PMID 28849045›Full record

ArticleMolecular medicine reports2017

Ultrasound and magnetic resonance molecular imaging of atherosclerotic neovasculature with perfluorocarbon magnetic nanocapsules targeted against vascular endothelial growth factor receptor 2 in rats.

Hua Chen, Lianglong Chen, Rongxi Liang, Jin Wei

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Photodynamic Therapy for Atherosclerosis.International journal of molecular sciences · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Perfluorocarbons-BasedInternational journal of nanomedicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hua ChenDepartment of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Heart Disease, Fuzhou, Fujian 350001, P.R. China.
Lianglong ChenDepartment of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Heart Disease, Fuzhou, Fujian 350001, P.R. China.
Rongxi LiangDepartment of Ultrasonography, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China.
Jin WeiDepartment of Imaging, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China.
Fujian Medical University · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to investigate the feasibility of using ultrasonography (US) and magnetic resonance (MR) for bimodal molecular imaging of atherosclerotic neovasculature with liquid perfluorocarbon magnetic nanocapsules (NCs) targeted to vascular endothelial growth factor receptor 2 (VEGFR‑2). By incorporating perfluorooctyl bromide (PFOB) and superparamagnetic iron oxide (SPIO) into polylactic acid, a SPIO‑embedded PFOB NC was constructed; subsequently, a VEGFR‑2‑targeted NC (VTNC) containing dual detectable probes was created by covalently linking a VEGFR‑2 antibody onto the surface of the SPIO‑embedded PFOB NC. Target specificity was verified in vitro by incubating VTNC with VEGFR‑2+ or VEGFR‑2‑ endothelial cells. Rats with vulnerable plaques were assigned to receive either an injection of VTNC (Targeted group; n=8) or an injection of NC (Nontargeted group; n=8); control rats also received an injection of VTNC (Control group; n=8). US and MR imaging of the abdominal aorta were performed to detect VTNC by measuring of the ultrasonic grayscale intensity (GSI) and MR contrast‑to‑noise ratio (CNR) prior to and at successive time points following VTNC and NC injections. The percent positive area (PPA) of CD31+ (PPACD31+) or VEGFR‑2+ (PPAVEGFR‑2+) expression was quantified by immunohistochemical staining. CD31 was used to verify the existence of endothelial cells as it is widely expressed on the surface of endothelial cells whether activated or not. The results demonstrated that VTNC was able to highly and selectively detect VEGFR‑2+ endothelial cells, and GSI, CNR, PPACD31+ and PPAVEGFR‑2+ were significantly increased in the targeted group compared with the nontargeted and control groups. In the control group, no atherosclerotic plaques or angiogenesis was identified, thus no expression of PPACD31+ and PPAVEGFR‑2 (data not shown). There were strong correlations among GSI, CNR, PPACD31+ and PPAVEGFR‑2+. In conclusion, two‑probe VTNC is feasible for bimodal US and MR molecular imaging of atherosclerotic neovasculature, which may offer complementary information for the more reliable prediction of plaque vulnerability.

Indexed as

AnimalsAntibodiesAortaAtherosclerosisCattleContrast MediaDisease Models, AnimalDrug CompoundingEndothelial CellsFerric CompoundsFluorocarbonsHydrocarbons, BrominatedMagnetic Resonance ImagingMaleNanocapsulesNeovascularization, PathologicAntibodiesContrast MediaFerric Compoundsferric oxideFluorocarbonsHydrocarbons, BrominatedKdr protein, ratNanocapsulesperflubronVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID28849045
PMCPMC5865790
OpenAlexW2748773641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.